Skip to main content
    A

    Adaptive Biotechnologies Corp (ADPT)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $27.98
    +1.15 (+4.29%)

    Market Cap: $4.26B

    Last updated: Nov 06, 2026 at 4:20 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    87%(26/30)
    Avg Surprise
    +16.09%
    Streak
    12 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.15
    Range$-0.18 - $-0.12
    7 analysts
    Revenue Consensus
    $95M
    Range$93M - $99M
    8 analysts
    Last 12 of 31 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.15$-0.18 - $-0.12--7--
    Sep 26
    Reported Nov 4
    		$0.02N/A-+120.00%Beat7
    7
    0
    30d
    		+113.3%
    Jun 26
    Reported Jul 28
    		$-0.10$-0.13$-0.15 - $-0.11+23.08%Beat7
    2
    3
    30d
    		+41.2%
    Mar 26
    Reported May 5
    		$-0.13$-0.16$-0.20 - $-0.15+18.75%Beat7
    0
    1
    30d
    		+35.0%
    Dec 25
    Reported Feb 5
    		$-0.09$-0.18-+50.00%Beat7
    1
    1
    30d
    		+60.9%
    Sep 25
    Reported Nov 5
    		$-0.15$-0.16$-0.22 - $0.01+6.25%Beat7
    2
    0
    30d
    		+31.8%
    Jun 25
    Reported Aug 5
    		$-0.17$-0.24$-0.26 - $-0.22+29.17%Beat5
    1
    0
    30d
    		+41.4%
    Mar 25
    Reported May 1
    		$-0.20$-0.31$-0.34 - $-0.28+35.48%Beat3
    0
    4
    30d
    		+37.5%
    Dec 24
    Reported Feb 11
    		$-0.23$-0.24$-0.27 - $-0.21+4.17%Beat4
    5
    0
    30d
    		+23.3%
    Sep 24
    Reported Nov 7
    		$-0.22$-0.27$-0.35 - $-0.24+18.52%Beat8
    1
    0
    30d
    		+37.1%
    Jun 24
    Reported Aug 1
    		$-0.29$-0.33$-0.37 - $-0.27+12.12%Beat8
    No revisions (30d)
    		+12.1%
    Mar 24
    Reported May 7
    		$-0.32$-0.34$-0.37 - $-0.31+5.88%Beat7
    No revisions (30d)
    		+20.0%
    Dec 23
    Reported Feb 14
    		$-0.30$-0.33$-0.36 - $-0.30+9.09%Beat8
    0
    1
    30d
    		-7.1%

    Key Metrics

    Valuation
    P/E Ratio-93.27EV/EBITDAN/A
    Price/FCF-508.73xFCF Yield-0.20%
    Profitability
    Profit Margin-20.70%Operating Margin-22.00%
    ROE-38.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-1.47x
    Current Ratio3.97xQuick Ratio3.87x
    Trading Statistics
    Beta2.15Avg Volume2.16M
    52-Week High$30.7452-Week Low$12.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$26.95
    SMA 20$25.96
    SMA 50$26.42
    SMA 200$19.82
    EMA 10$26.71
    EMA 20$26.51
    EMA 50$25.98
    EMA 200$21.26

    MACD

    Line: 0.18Signal: 0.01Hist: 0.17

    ADX

    ADX: 14.7+DI: 21.8-DI: 18.4

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down60.0
    PSAR$28.72

    Bollinger Bands

    Upper Band$28.65
    Lower Band$23.27
    %B Position2074%(Upper)
    Band Width0.88

    RSI (14-Day)

    Neutral
    57.2

    Momentum Oscillators

    Stoch %K64.1
    Stoch %D51.1
    Williams %R-20.5
    ROC (10d)9.7%
    Momentum2.47
    CCI (20d)112.4
    MFI (14d)75.4

    Volatility Measures

    ATR (14d)$1.65(5.9%)
    StdDev (20d)1.35
    Hist Vol57.6%(High)

    Volume Flow

    VWAP$27.60
    OBV61.2M
    AD Line40.4M
    CMF (20d)0.037

    Volume Metrics

    Avg Vol (20d)2.2M
    Vol Ratio1.5x(High)
    VWMA (20d)$26.21

    Pivot Points

    R3$30.78
    R2$29.44
    R1$28.14
    Pivot Point$26.80
    S1$25.50
    S2$24.16
    S3$22.86

    Advanced Oscillators

    TSI3.07
    Ultimate Osc49.8
    KST0.22

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$83.90M$71.55M$70.87M$71.68M$93.97M$58.88M$52.44M$47.46M$46.44M$43.19M$41.87M$45.78M
    Cost of Revenue$19.93M$20.16M$18.71M$18.22M$18.16M$18.00M$16.98M$18.05M$16.67M$19.32M$18.05M$19.62M
    Gross Profit$63.97M$51.39M$52.17M$53.46M$75.82M$40.88M$35.46M$29.41M$29.77M$23.87M$23.82M$26.17M
    Operating Expenses$64.43M$67.16M$71.37M$66.23M$65.53M$65.92M$65.07M$63.25M$62.40M$71.19M$72.58M$97.24M
    R&D$18.64M$19.15M$23.62M$21.76M$23.67M$24.13M$24.20M$23.19M$24.16M$25.35M$30.25M$28.75M
    SG&A$18.46M$21.17M$20.98M$19.56M$17.96M$17.79M$17.40M$18.06M$17.26M$17.89M$19.60M$20.73M
    Operating Income$-457,000$-15,770,000$-19,206,000$-12,773,000$10.29M$-25,036,000$-29,604,000$-33,837,000$-32,632,000$-47,318,000$-48,762,000$-71,068,000
    Interest Income$3.77M$2.26M$2.08M$2.15M$2.23M$2.39M$2.68M$3.07M$3.47M$3.77M$4.22M$4.61M
    Interest Expense$503,000$26.43M$2.89M$2.95M$2.97M$2.95M$2.90M$2.95M$2.94M$2.70M$2.99M$3.01M
    Income Before Tax$2.81M$-39,941,000$-20,015,000$-13,579,000$9.54M$-25,593,000$-29,830,000$-33,717,000$-32,097,000$-46,248,000$-47,533,000$-69,467,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$2.81M$-39,941,000$-20,015,000$-13,579,000$9.54M$-25,593,000$-29,830,000$-33,717,000$-32,097,000$-46,248,000$-47,533,000$-69,467,000
    EBITDA$2.50M$-12,187,000$-15,505,000$-8,866,000$14.18M$-21,284,000$-25,831,000$-30,847,000$-30,049,000$-44,414,000$-46,191,000$-68,635,000
    EBIT$-457,000$-15,770,000$-19,206,000$-12,773,000$10.29M$-25,036,000$-29,604,000$-33,837,000$-32,632,000$-47,318,000$-48,762,000$-71,068,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ADPT

    Government Contracts

    Gov Obligations (TTM)
    $251000
    Gov Obligations / Revenue
    0.1%
    Obligations YoY
    N/A
    Active Awards
    9
    New Awards (TTM)
    2
    Avg Remaining Term
    6.4 mo

    Top agency: Department of Defense at 50.8% of trailing twelve month obligations across 2 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C25026P0251Department of Veterans AffairsDepartment of Veterans Affairs$243750Dec 29, 2025
    36C24126N0614Department of Veterans AffairsDepartment of Veterans Affairs$35100Jul 15, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Form 4 Adaptive Biotechnologies Corp: Julie Rubinstein (President and COO) For: 4 November

    This article reports on a Form 4 filing for Adaptive Biotechnologies Corp, detailing a transaction by Julie Rubinstein, the company's President and COO...

    Investing.com India•11/6/26•Neutral

    Form 4 Adaptive Biotechnologies Corp: Julie Rubinstein (President and COO) For: 4 November

    This article reports on a Form 4 filing for Adaptive Biotechnologies Corp, detailing an insider transaction involving Julie Rubinstein, the company's President and COO...

    Investing.com UK•11/6/26•Neutral

    The COO of Adaptive Biotechnologies (ADPT) exercises $12.14 options and sells 35,643 shares.

    Adaptive Biotechnologies President and COO Julie Rubinstein exercised 35,643 stock options at $12.14 per share across November 4, 5, and 6, 2026...

    Stock Titan•11/6/26•Somewhat-Bearish

    Quarterly Sales Slip Might Change The Case For Investing In Adaptive Biotechnologies (ADPT)

    Adaptive Biotechnologies (ADPT) reported a sales slip in Q3 2026 to US$83.9 million from US$93.97 million year-over-year, with net income falling to US$2.88 million. Despite higher nine-month sales...

    Simply Wall St•11/5/26•Somewhat-Bearish

    Adaptive Biotechnologies Q3FY26 Results: Revenue rises 39% to $83.9 million

    Adaptive Biotechnologies reported strong third-quarter 2026 financial results, with total revenue increasing by 39% year-over-year to $83.9 million...

    scanx.trade•11/5/26•Bullish

    ADPT Valuation and Fair Value

    P/E
    -93.3x
    P/FCF
    -508.7x
    PEG
    0.0x
    P/B
    25.5x
    See GNG's fair value

    ADPT Profitability: Margins, ROIC and FCF

    Gross margin
    74.2%
    Operating margin
    -22.0%
    Net margin
    -20.7%
    ROE
    -38.8%
    FCF margin
    -3.0%
    FCF yield
    -0.2%

    ADPT Competitors

    CompanyTicker
    Indivior PLC Ordinary SharesINDV
    Edgewise Therapeutics IncEWTX
    Integer Holdings CorpITGR
    ICU Medical IncICUI
    Legend Biotech CorpLEGN
    Premier IncPINC
    iRhythm Technologies IncIRTC
    Pulse Biosciences IncPLSE

    Sector: Healthcare

    ADPT Analyst Ratings

    Consensus
    Buy
    Analysts
    9
    Strong Buy
    2
    Buy
    6
    Hold
    1
    Sell
    0
    Strong Sell
    0

    ADPT Bull Case vs Bear Case

    Bull case

    • ADPT beat EPS estimates in 100.0% of its last 8 reported quarters.
    • ADPT grew quarterly revenue 21.5% year over year.
    • 88.9% of ADPT's analyst ratings are Buy or Strong Buy.

    Bear case

    • ADPT has a -20.7% net profit margin.

    ADPT Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    35.9%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.15

    ADPT Earnings Date

    ADPT reports Feb 3, 2027, after the close. The date is estimated.

    ADPT Earnings Call

    The latest ADPT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    ADPT ETF Holders

    GNG tracks 13 ETFs that hold ADPT. The largest weights:

    1. ARK Genomic Revolution ETF (ARKG), 2.27% of the fund
    2. abrdn Healthcare Investors (HQH), 0.82% of the fund
    3. First Trust Small Cap Growth AlphaDEX Fund (FYC), 0.56% of the fund
    4. Fidelity Enhanced Small Cap Core ETF (FESM), 0.34% of the fund
    5. iShares Biotechnology ETF (IBB), 0.30% of the fund
    Open the ETF Stock Exposure tool for ADPT

    See insider activity

    Frequently Asked Questions About ADPT

    When does ADPT report earnings?

    Adaptive Biotechnologies Corp (ADPT) is expected to report earnings on Feb 3, 2027.

    Does ADPT pay dividends?

    Adaptive Biotechnologies Corp (ADPT) does not currently pay a regular dividend.

    What is ADPT's market cap?

    Adaptive Biotechnologies Corp (ADPT) has a market capitalization of $4.26B with a current stock price of $27.98.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In